Archive Category: Green Zone Fortunes Updates

What’s Up With Hims and “Nasty Novo”?

Something fishy is going on here… After only two months, Danish pharmaceutical giant Novo Nordisk and Hims & Hers Health (HIMS) have ended a deal that looked like a home run for both companies. Hims would distribute Novo’s hit GLP-1 weight-loss drug Wegovy, providing broader access to the popular treatment — and a windfall of new revenue for both companies.

Read More

Above and Beyond “Magnificent” Returns

Palantir Technologies (PLTR) has been absolutely crushing the market since I recommended adding it to your portfolio last March. Shares are currently up 500%, and I sincerely hope you took the opportunity to position yourself for that move. (If you did act, I’d obviously love to hear about it! Shoot me a quick email at GreenZone@MoneyandMarkets.com and tell me how much you invested and are up.)

Read More

Tap Into Global Financial System With This “Tariff-Proof” Derivatives Exchange

President Trump’s transformative new trade agenda sent the stock market on a rollercoaster ride over the last two months. And while the S&P 500 has very nearly regained its previous footing — the future of numerous industries and longtime trade partners still hangs in the balance. Meanwhile, trading volume is surging across numerous platforms, with one exchange recording an all-time high of 1.1 billion new contracts in a single quarter.

Read More

Sign-up == X1904104

Conquering the Market Starts Here ...

In his free newsletter, What My System Says Today, Adam O’Dell uses his Green Zone Power Rating system to keep you in the know and focused on the market’s best (and worst) opportunities. It’s a data-driven approach underpinned by Wall Street-caliber tools you can only get here at Money & Markets. Sign up for FREE access to our daily emails now!

Recent Articles

Watchlist